1. Home
  2. LIXT vs GROW Comparison

LIXT vs GROW Comparison

Compare LIXT & GROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lixte Biotechnology Holdings Inc.

LIXT

Lixte Biotechnology Holdings Inc.

N/A

Current Price

$3.56

Market Cap

26.5M

Sector

Health Care

ML Signal

N/A

Logo U.S. Global Investors Inc.

GROW

U.S. Global Investors Inc.

HOLD

Current Price

$2.59

Market Cap

31.3M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
LIXT
GROW
Founded
2005
1968
Country
United States
United States
Employees
3
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
26.5M
31.3M
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
LIXT
GROW
Price
$3.56
$2.59
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
37.1K
34.8K
Earning Date
05-08-2026
05-11-2026
Dividend Yield
N/A
3.37%
EPS Growth
N/A
N/A
EPS
N/A
0.05
Revenue
N/A
$23,850,609.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$51.60
Revenue Growth
N/A
N/A
52 Week Low
$0.64
$2.09
52 Week High
$6.09
$3.65

Technical Indicators

Market Signals
Indicator
LIXT
GROW
Relative Strength Index (RSI) 58.16 45.78
Support Level $2.50 $2.35
Resistance Level $4.45 $2.83
Average True Range (ATR) 0.28 0.14
MACD 0.06 0.02
Stochastic Oscillator 62.24 36.90

Price Performance

Historical Comparison
LIXT
GROW

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

About GROW U.S. Global Investors Inc.

US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.

Share on Social Networks: